Safety and tolerability of GRF6019 in mild‐to‐moderate Alzheimer's disease dementia

INTRODUCTION: This phase 2 trial evaluated the safety, tolerability, and feasibility of repeated infusions of the plasma fraction GRF6019 in mild‐to‐moderate Alzheimer's disease. METHODS: In this randomized, double‐blind, dose‐comparison trial, 47 patients were randomized 1:1 to receive daily i...

Descripción completa

Detalles Bibliográficos
Autores principales: Hannestad, Jonas, Koborsi, Katie, Klutzaritz, Vicki, Chao, Whitney, Ray, Rebecca, Páez, Antonio, Jackson, Sam, Lohr, Scott, Cummings, Jeffrey L., Kay, Gary, Nikolich, Karoly, Braithwaite, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744029/
https://www.ncbi.nlm.nih.gov/pubmed/33344754
http://dx.doi.org/10.1002/trc2.12115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744029/
https://www.ncbi.nlm.nih.gov/pubmed/33344754
http://dx.doi.org/10.1002/trc2.12115

Ejemplares similares